AML With Myelodysplasia-related Features - 27 Studies Found
Terminated |
: Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission :
: Drug: bortezomib Given SC Other Names: |
Completed |
: Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia :
: |
Completed |
: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies :
: |
Completed |
: Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia :
: |
Completed |
: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia :
: |
Completed |
: Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes :
: |
Completed |
: Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia :
: |
Completed |
: Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
: |
Active, not recruiting |
: Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission :
: |
Completed |
: Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia :
: |